224 results on '"Hansel, Donna E."'
Search Results
2. Plasmacytoid Urothelial Carcinoma of the Urinary Bladder – a Clinicopathological and Molecular Analysis of 52 Cases
3. MORPHOLOGICAL PROGRESSION IN RELAPSING PATIENTS WITH SMALL CELL BLADDER CANCER
4. The IL6/JAK/STAT3 signaling axis is a therapeutic vulnerability in SMARCB1-deficient bladder cancer
5. Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract
6. Gender differences in appointments to pathology department interim chair positions and subsequent advancement to permanent chair positions
7. Supp Figure 4 from Nuclear CD24 Drives Tumor Growth and Is Predictive of Poor Patient Prognosis
8. Data from A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors
9. Supp Figure 2 from Nuclear CD24 Drives Tumor Growth and Is Predictive of Poor Patient Prognosis
10. Supplementary Tables from Androgen Receptor Regulates CD44 Expression in Bladder Cancer
11. Data from Nuclear CD24 Drives Tumor Growth and Is Predictive of Poor Patient Prognosis
12. Supplementary Information from Nuclear CD24 Drives Tumor Growth and Is Predictive of Poor Patient Prognosis
13. Supplementary Figure S1 from The Investigational Aurora Kinase A Inhibitor MLN8237 Induces Defects in Cell Viability and Cell-Cycle Progression in Malignant Bladder Cancer Cells In Vitro and In Vivo
14. Supplementary Figure S2 from The Investigational Aurora Kinase A Inhibitor MLN8237 Induces Defects in Cell Viability and Cell-Cycle Progression in Malignant Bladder Cancer Cells In Vitro and In Vivo
15. Supp Figure 3 from Nuclear CD24 Drives Tumor Growth and Is Predictive of Poor Patient Prognosis
16. Supp Figure 5 from Nuclear CD24 Drives Tumor Growth and Is Predictive of Poor Patient Prognosis
17. Supplementary Figure 5 from Androgen Receptor Regulates CD44 Expression in Bladder Cancer
18. Supplementary Information from Nuclear CD24 Drives Tumor Growth and Is Predictive of Poor Patient Prognosis
19. Supplementary Figure 6 from Androgen Receptor Regulates CD44 Expression in Bladder Cancer
20. Supplementary Figure Legends from The Investigational Aurora Kinase A Inhibitor MLN8237 Induces Defects in Cell Viability and Cell-Cycle Progression in Malignant Bladder Cancer Cells In Vitro and In Vivo
21. Supp Figure 1 from Nuclear CD24 Drives Tumor Growth and Is Predictive of Poor Patient Prognosis
22. Supp Figure 5 from Nuclear CD24 Drives Tumor Growth and Is Predictive of Poor Patient Prognosis
23. Data from Nuclear CD24 Drives Tumor Growth and Is Predictive of Poor Patient Prognosis
24. Supp Figure 1 from Nuclear CD24 Drives Tumor Growth and Is Predictive of Poor Patient Prognosis
25. Supp Figure 3 from Nuclear CD24 Drives Tumor Growth and Is Predictive of Poor Patient Prognosis
26. Supplementary Data from CD24 Offers a Therapeutic Target for Control of Bladder Cancer Metastasis Based on a Requirement for Lung Colonization
27. Data from CD24 Offers a Therapeutic Target for Control of Bladder Cancer Metastasis Based on a Requirement for Lung Colonization
28. Supplementary Data from CD24 Offers a Therapeutic Target for Control of Bladder Cancer Metastasis Based on a Requirement for Lung Colonization
29. Data from CD24 Offers a Therapeutic Target for Control of Bladder Cancer Metastasis Based on a Requirement for Lung Colonization
30. The Many Faces of Muscle-Invasive Bladder Cancer: Histopathological and Molecular Characterization
31. Community-Based SARS-CoV-2 Testing Using Saliva or Nasopharyngeal Swabs to Compare the Performance of Weekly COVID-19 Screening to Wastewater SARS-CoV-2 Signals
32. Response to Immunotherapy: Application of Molecular Pathology to Predict Successful Response
33. Emerging Molecular Approaches in the Analysis of Urine in Bladder Cancer Diagnosis
34. Uncommon Cancers of the Bladder
35. Bimodal distribution pattern associated with the PCR cycle threshold (Ct) and implications in COVID-19 infections
36. Using Spike Gene Target Failure to Estimate Growth Rate of the Alpha and Omicron Variants of SARS-CoV-2
37. MRI appearance of BRCA-associated prostate cancer
38. Emerging Roles for Mammalian Target of Rapamycin (mTOR) Complexes in Bladder Cancer Progression and Therapy
39. Bimodal Distribution Pattern Associated With The PCR Cycle Threshold (Ct) And Implications In COVID-19 Infections
40. Renal Pelvis and Ureter
41. Urethra
42. Pediatric Renal Neoplasms
43. Emerging and Recently Described Subtypes of Renal Carcinoma
44. Characterization of Cellular and Acellular Analytes from Pre-Cystectomy Liquid Biopsies in Patients Newly Diagnosed with Primary Bladder Cancer
45. Bladder Cancer Invasion Is Mediated by Mammalian Target of Rapamycin Complex 2–Driven Regulation of Nitric Oxide and Invadopodia Formation
46. Pathology
47. Urothelial Carcinoma Variants: Morphology and Association with Outcomes
48. Updated pathology reporting standards for bladder cancer: biopsies, transurethral resections and radical cystectomies
49. Refining neoadjuvant therapy clinical trial design for muscle-invasive bladder cancer before cystectomy: a joint US Food and Drug Administration and Bladder Cancer Advocacy Network workshop
50. Comparison of SARS-CoV-2 PCR-Based Detection Using Saliva or Nasopharyngeal Swab Specimens in Asymptomatic Populations
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.